Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemziviptadil in hospitalized COVID-19 patients
NCT04433546Phase 2Terminated
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pemziviptadil in coronavirus disease 2019 (COVID-19), sponsored by PhaseBio Pharmaceuticals. Started Jul 2020; status: terminated.
02
Drugs
pemziviptadil
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04433546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433546.